Stem cell factor (SCF), also known as mast cell growth factor, kit ligand, and steel factor, is the ligand for the tyrosine kinase receptor (SCFR) that is encoded by the c-kit proto-oncogene. We analyzed the effects of recombinant human SCF (r-hSCF, 5-50 micrograms/kg/day, injected subcutaneously) on mast cells and melanocytes in a phase I study of 10 patients with advanced breast carcinoma. A wheal and flare reaction developed at each r-hSCF injection site; by electron microscopy, most dermal mast cells at these sites exhibited extensive, anaphylactic-type degranulation. A 14-d course of r-hSCF significantly increased dermal mast cell density at sites distant to those injected with the cytokine and also increased both urinary levels of the major histamine metabolite, methyl-histamine, and serum levels of mast cell alpha-tryptase. Five subjects developed areas of persistent hyperpigmentation at r-hSCF injection sites; by light microscopy, these sites exhibited markedly increased epidermal melanization and increased numbers of melanocytes. The demonstration that r-hSCF can promote both the hyperplasia and the functional activation of human mast cells and melanocytes in vivo has implications for our understanding of the role of endogenous SCF in health and disease. These findings also indicate that the interaction between SCF and its receptor represents a potential therapeutic target for regulating the numbers and functional activity of both mast cells and cutaneous melanocytes.
Skip Nav Destination
Article navigation
1 June 1996
Article|
June 01 1996
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.
J J Costa,
J J Costa
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
G D Demetri,
G D Demetri
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
T J Harrist,
T J Harrist
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
A M Dvorak,
A M Dvorak
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
D F Hayes,
D F Hayes
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
E A Merica,
E A Merica
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
D M Menchaca,
D M Menchaca
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
A J Gringeri,
A J Gringeri
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
L B Schwartz,
L B Schwartz
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
S J Galli
S J Galli
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Search for other works by this author on:
J J Costa
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
G D Demetri
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
T J Harrist
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
A M Dvorak
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
D F Hayes
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
E A Merica
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
D M Menchaca
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
A J Gringeri
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
L B Schwartz
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
S J Galli
Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 183 (6): 2681–2686.
Citation
J J Costa, G D Demetri, T J Harrist, A M Dvorak, D F Hayes, E A Merica, D M Menchaca, A J Gringeri, L B Schwartz, S J Galli; Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.. J Exp Med 1 June 1996; 183 (6): 2681–2686. doi: https://doi.org/10.1084/jem.183.6.2681
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement